Previous 10 | Next 10 |
Aimed at identifying suitable patients for RAVICTI (glycerol phenylbutyrate) Oral Liquid, Horizon Therapeutics ( HZNP -2.3% ) launches a free-of-charge urea cycle disorder (UCD) genetic testing program with Invitae ( NVTA -2% ). More news on: Horizon Therapeutics Public Limited Compa...
-- New program improves access and speed to receiving a diagnosis for people and extended family members who may be living with Urea Cycle Disorders -- Horizon Therapeutics plc (Nasdaq: HZNP) in partnership with Invitae Corporation (NYSE: NVTA) today announced a new urea cycle disorde...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2019. Please visit our Tracking John Paulson's Pau13lson & Company Portfolio ser...
Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been selected to the FORTUNE and Great Place to Work® 2019 “ Best Workplaces in Chicago ” list. Horizon ranked as one of the top 55 companies in the Chicago area. “We are proud to be reco...
-- Research that has redefined the trajectory and true impact of the disease underscores the campaign -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of Gout Lies , a data-driven campaign to reframe physician dialogue on the reality of living with gout ...
The U.S. Court of Appeals for the Federal Circuit has reversed a lower court decision over the alleged infringement by generic competitors of two U.S. patents covering Horizon Therapeutics' ( HZNP -1% ) Vimovo (naproxen/esomeprazole magnesium). More news on: Nuvo Pharmaceuticals I...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that Tina Ventura, senior vice president, investor relations, has been named a 2019 Healthcare Businesswomen's Association (HBA) Luminary. Tina will be honored today at the 30 th annual Woman of the Year event in New Yor...
Merck & Co ( MRK ) - The company announced results from the phase 2 study of V114 (15-valent pneumococcal conjugate vaccine) as compared to currently available 13-valent pneumococcal conjugate vaccine in healthy infants 6-12 weeks of age. The primary endpoint was met by demonstrating n...
Horizon Therapeutics PLC (HZNP) Q1 2019 Earnings Conference Call May 08, 2019 08:00 AM ET Company Participants Tina Ventura - Senior Vice President of Investor Relations Tim Walbert - Chairman, President and Chief Executive Officer Shao-Lee Lin - Executive Vice President, Head of...
The following slide deck was published by Horizon Pharma plc in conjunction with their 2019 Q1 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...